New paper from the French EPICAP (Epidemiological study of prostate cancer) study [1].
"EPICAP is a population-based case-control study conducted in the département of Hérault in France. Eligible cases are all cases of prostate cancers newly diagnosed in 2012-2013 in men less than 75 years old and residing in the département of Hérault at the time of diagnosis. Controls are men of the same age as the cases and living in the département of Hérault, recruited in the general population.The sample will include a total of 1000 incident cases of prostate cancer and 1000 population-based controls over a 3-year period (2012-2014).The cases and controls are face-to-face interviewed using a standardized computed assisted questionnaire. The questions focus primarily on usual socio-demographic characteristics, personal and family medical history, lifestyle, leisure activities, residential and occupational history. Anthropometric measures and biological samples are also collected for cases and controls." [2]
Not sure that we needed yet another NSAID study.
I have previously posted on the importance of markers of subclinical inflammation. Inflammation that is undiagnosed/untreated has an impact on mortality, in general, & PCa death in particular. Chronic users of NSAIDs (other than prophylactic low-dose aspirin) are presumably looking for pain control, rather than normalization of C-reactive protein [CRP], albumin, etc, etc, but a lower rate of PCa incidence or mortality would suggest that there is benefit in monitoring & addressing inflammation markers.
"All-NSAIDs use was inversely associated with prostate cancer" (21% less risk) "especially in men using NSAIDs that preferentially inhibit COX-2 activity (52% less risk)"
Nonaspirin NSAIDs users had a decreased risk of prostate cancer" (28% less risk) "particularly among men with an aggressive prostate cancer" (51% less risk) "and in men with a personal history of prostatitis" (79% less risk!!!)
"Our results are in favor of a decreased risk of prostate cancer in men using NSAIDs, particularly for men using preferential anti-COX-2 activity. The protective effect of NSAIDs seems to be more pronounced in aggressive prostate cancer and in men with a personal history of prostatitis, but this needs further investigations to be confirmed."
-Patrick
antihypertensive drug syrosingopine enhances metformin's anti-cancer efficacy.
The human microbiome and its link in prostate cancer risk and pathogenesis
Does anyone have multivitamin/progression data?
Antidepressant medication use and prostate cancer recurrence in men with depressive disorders. 
Study Finds: Drug typically used in cancer therapy emerges as powerful anti-aging remedy
